Hovione, an East Windsor-based fully-integrated global Contract Development and Manufacturing Organization (CDMO), on Monday announced the completion of an initial multi-million-dollar investment cycle to significantly expand its manufacturing site in East Windsor. This initial phase of a major expansion strategy involved an investment of $100 million aimed at bolstering U.S. operations and integrated drug substance and drug product capabilities.
The expansion is centered on a new 31,000-square-foot facility that will house two size-3 spray dryers (PSD-3) dedicated to the production of Amorphous Solid Dispersions (ASDs). This investment more than doubles Hovione’s spray drying capacity in the United States, addressing growing customer demand for North American supply nodes. Spray drying is a critical technology used to improve drug solubility and bioavailability, a factor that could benefit the development of up to 70% of new drugs. Construction is underway, with GMP operations scheduled to commence in the second quarter of 2026.
“Since launching our New Jersey operations in 2002, Hovione has been one of the longest established European CDMOs in the United States,” Jean-Luc Herbeaux, CEO of Hovione said. “This investment reinforces Hovione’s leadership in spray drying – a core technology platform where we have built extensive know-how and capabilities. By continuing to advance our platforms and expand capacity in the U.S., we are strengthening the foundation that enables our partners to bring complex medicines to patients more efficiently.”
Herbeaux emphasized that the investment addresses the need for U.S.-based capacity and integrated solutions that streamline development. “By consolidating development, scale-up, and commercial manufacturing within a single quality and governance framework, we provide customers with seamless execution from drug substance to drug product,” he added.
Looking ahead, Hovione has also acquired additional adjacent land, a 125,000-square-foot greenfield, to support future growth. This space is planned for large-scale production, including continuous and batch tableting capacity, and will introduce the next generation of pharmaceutical technologies and R&D capabilities.
David Basile, vice president of Technical Operations – Americas at Hovione, commented, “We are integrating our teams, specialized assets, proprietary technologies, and digital systems to deliver distinctive end-to-end ASD and continuous tableting platforms to our customers. Through our new strategic engagement model, customers can gain privileged access to innovation and assets that accelerate their programs and create long-term value.”
The East Windsor expansion is part of a wider international growth plan that includes capacity investments in Ireland and Portugal, creating a globally harmonized network of sites for the commercialization of APIs, drug product intermediates, and drug products.
